Arbutus Biopharma Newsroom

Express News | Morgan Stanley Reports 10.3% Passive Stake in Arbutus Biopharma Corp as of May 31- SEC Filing

BreakingsJun 11 04:54

Express News | HC Wainwright & Co. has reiterated its buy rating for arbutus biopharma (ABUS.US), with a target price adjusted from $5.00 to $5.00.

BreakingsJun 7 23:30

Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4

Chardan Capital analyst Keay Nakae maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.2% an

Futu NewsJun 7 10:32

Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk

Dow JonesJun 7 02:54

Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024

BenzingaJun 6 23:16

Express News | Treatment With Arbutus’ Imdusiran and Vtp-300 Achieves Statistical Significance in Lowering Hbsag Levels

BreakingsJun 6 23:15

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

Analyst UpgradesJun 6 18:36

H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5

H.C. Wainwright analyst Ed Arce maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 40.0% and a

Futu NewsJun 6 18:33

Treatment With Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus BiopharmaJun 6 12:00

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow JonesJun 6 04:30

Express News | Chardan Capital: Maintains buy rating for Arbutus Biopharma (ABUS.US) and adjusts target price from $4.00 to $4.00.

BreakingsJun 6 04:20

Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $4 Price Target

Analyst UpgradesJun 6 04:20

JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4

JMP Securities analyst Roy Buchanan maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 32.2% a

Futu NewsJun 6 02:32

Express News | Arbutus’ Imdusiran With Short Course Interferon Achieves Sustained Undetectable Hbsag, a Necessity for Hbv Functional Cure

BreakingsJun 5 14:30

RNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd.

PR NewswireJun 4 18:34

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus BiopharmaMay 29 12:00

Arbutus Biopharma Shareholders Approve Board Changes and Plan Expansion

TipRanksMay 29 06:04

Arbutus to Present Imdusiran Data at EASL Congress 2024

GlobeNewswireMay 22 14:00

Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents

BenzingaMay 21 00:52

Sector Update: Health Care Stocks Softer Friday Afternoon

MT NewswiresMay 18 01:53